Payment overview · 2025
General Payments
$334.40
18 reported records · 12 companies
Healthcare provider profile · identity verified
Dee G Mccrary, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, TX · NPI 1942203278
Verified facts
What the public records show
CMS Open Payments records show Dee G Mccrary, MD received $334.40 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.11 | 21.6% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.60 | 13.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.59 | 10.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.06 | 8.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.65 | 8.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.35 | 7.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.58 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.52 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.51 | 4.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.19 | 4.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.28 | 4.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.96 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.40 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.60 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 575 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 87 |
| Gabapentin | Gabapentin | 248 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 78 |
| Lisinopril | Lisinopril | 174 | 68 |
| Omeprazole | Omeprazole | 174 | 57 |
| Metformin Hcl | Metformin Hcl | 137 | 48 |
| Furosemide | Furosemide | 130 | 42 |
| Potassium Chloride | Potassium Chloride | 130 | 39 |
| Alprazolam | Alprazolam | 110 | 42 |
| Allopurinol | Allopurinol | 101 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 37 |
| Losartan Potassium | Losartan Potassium | 99 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 29 |
| Trazodone Hcl | Trazodone Hcl | 80 | 31 |
| Carvedilol | Carvedilol | 78 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 29 |
| Montelukast Sodium | Montelukast Sodium | 71 | 23 |
| Sertraline Hcl | Sertraline Hcl | 67 | 20 |
| Eliquis | Apixaban | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Simvastatin | Simvastatin | 61 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 23 |
| Tramadol Hcl | Tramadol Hcl | 55 | 20 |
| Glimepiride | Glimepiride | 53 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Finasteride | Finasteride | 48 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 23 |
| Meloxicam | Meloxicam | 47 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 30 |
| Ozempic | Semaglutide | 43 | 13 |
| Methylprednisolone | Methylprednisolone | 41 | 36 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 39 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Celecoxib | Celecoxib | 38 | 22 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Prednisone | Prednisone | 38 | 22 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 18 |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 14 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 12 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Cephalexin | Cephalexin | 19 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.40 · 18 records | AstraZeneca Pharmaceuticals LP | Auvelity, BREZTRI, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, Fluad, Flucelvax, Kerendia, Korlym, Qelbree, VRAYLAR, Veozah, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error